Frontiers in endocrinology · 2026
Anoctamin 5 mutation leads to abnormal bone homeostasis of GDD by regulating AMPK-dependent glucose metabolism.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Hongyu, Xu Huichong, Sun Kaiwen, Wang Shengnan, Zhang Mingyue, Lin Liqi, Zhang Shuai, Dong Rui, Hu Ying
Аннотация
INTRODUCTION: Gnathodiaphyseal Dysplasia (GDD) characterized by enhanced bone mass and spontaneous fractures is a rare autosomal dominant genetic disease caused by Anoctamin 5 (ANO5) mutations. Deletion or mutation in ANO5 exhibited abnormal bone metabolism of GDD manifested by increased osteogenesis and reduced osteoclastogenesis. However, the mechanism is not fully understood.
METHODS: Ano5Cys360Ty r knock-in mouse model was used. Mouse calvarial osteoblast (mCOB) and bone marrow macrophage (BMM) from homozygous knock-in (Ano5KI/KI) and wildtype mice were cultured in vitro. Compound C was selected to inhibit AMPK activity.
RESULTS: We found that Ano5Cys360Ty r mutation accelerated glycolysis and PGC1a-dependent mitochondrial respiration of osteoblast. Abnormal mitochondrial structure and function caused by PGC1b downregulation was observed in Ano5 KI/KI osteoclast. Furthermore, ANO5 mutation promoted the phosphorylation of AMPK, the classical sensor of energy metabolism. Inhibiting AMPK reduced glycolysis in osteoblast and maintained the mitochondrial homeostasis between osteoblast and osteoclast by suppressing PGC1a and promoting PGC1b respectively, to restrain bone formation and restore osteoclastogenesis. AMPK inhibitor reversed the bone phenotype of GDD by restraining bone formation and restoring osteoclastogenesis.
DISCUSSION: We highlighted the critical role of glucose metabolic distemperedness mediated by AMPK activation in GDD, which developing a potential therapeutic strategy targeted for treatment of GDD.
METHODS: Ano5Cys360Ty r knock-in mouse model was used. Mouse calvarial osteoblast (mCOB) and bone marrow macrophage (BMM) from homozygous knock-in (Ano5KI/KI) and wildtype mice were cultured in vitro. Compound C was selected to inhibit AMPK activity.
RESULTS: We found that Ano5Cys360Ty r mutation accelerated glycolysis and PGC1a-dependent mitochondrial respiration of osteoblast. Abnormal mitochondrial structure and function caused by PGC1b downregulation was observed in Ano5 KI/KI osteoclast. Furthermore, ANO5 mutation promoted the phosphorylation of AMPK, the classical sensor of energy metabolism. Inhibiting AMPK reduced glycolysis in osteoblast and maintained the mitochondrial homeostasis between osteoblast and osteoclast by suppressing PGC1a and promoting PGC1b respectively, to restrain bone formation and restore osteoclastogenesis. AMPK inhibitor reversed the bone phenotype of GDD by restraining bone formation and restoring osteoclastogenesis.
DISCUSSION: We highlighted the critical role of glucose metabolic distemperedness mediated by AMPK activation in GDD, which developing a potential therapeutic strategy targeted for treatment of GDD.